Anti-amyloid drugs: Potential in the treatment of diseases associated with aging

Drugs and Aging

Volumn 8, Issue 2, 1996, Pages 75-83

  Kisilevsky, Robert ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID PRECURSOR PROTEIN; COLCHICINE; DIMETHYL SULFOXIDE; DOXORUBICIN DERIVATIVE; ETHIONINE; HEPARAN SULFATE; SULFATE; SULFONIC ACID; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; AMYLOID NEUROPATHY; AMYLOIDOSIS; BASEMENT MEMBRANE; DIALYSIS; GENETICS; HUMAN; INFLAMMATION; KIDNEY FAILURE; LIVER TRANSPLANTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TURNOVER TIME;

EID: 0030046401     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199608020-00001     Document Type: Review

References (70)

1. Kazatchkine MD, Husby G, Araki S, et al. Nomenclature of amyloid and amyloidosis - WHO-IUIS Nomenclature SubCommittee. Bull World Health Organ 1993; 71: 105-8
2. Kisilevsky R, Subrahmanyan L. Serum amyloid A changes high density lipoprotein's cellular affinity: a clue to serum amyloid A's principal function. Lab Invest 1992; 66: 778-85
3. Banka CL, Yuan T, De Beer MC, et al. Serum amyloid A(SAA): influence on HDL-mediated cellular cholesterol efflux. J Lipid Res 1995; 36: 1058-65
4. Perlmutter LS, Chui HC. Microangiopathy, the vascular basement membrane and Alzheimers Disease - a review. Brain Res Bull 1990; 24: 677-86
5. Howard J, Pilkington GJ. Antibodies to fibronectin bind to plaques and other structures in Alzheimer's Disease and control brain. Neurosci Lett 1990; 118: 71-6
6. Perlmutter LS, Myers MA, Barron E. Vascular basement membrane components and the lesions of Alzheimer's disease: light and electron microscopic analyses. Microsc Res Tech 1994; 28: 204-15
7. Perlmutter LS. Microvascular pathology and vascular basement membrane components in Alzheimer's disease. Mol Neurobiol 1994; 9: 33-40
8. Kushner I, Rzewnicki DL. The acute phase response: general aspects. In: Husby G, editor. Clinical rheumatology: reactive amyloidosis and the acute phase response. London: Bailliere Tindall, 1994; 8 (3): 513-30
9. McAdam KPWJ, Elin RJ, Sipe JD, et al. Changes in human serum amyloid-A and C-reactive protein after etiocholanolone-induced inflammation. J Clin Invest 1978; 61: 390-4
10. Kisilevsky R, Gruys E, Shirahama T. Does amyloid enhancing factor (AEF) exist? Is AEF a single biological entity? Amyloid Int J Exp Clin Invest 1995; 2: 128-33
11. Kisilevsky R, Boudreau L. The kinetics of amyloid deposition. I. The effect of amyloid enhancing factor and splenectomy. Lab Invest 1983; 48: 53-9
12. Kisilevsky R, Benson MD, Axelrad MA, et al. The effect of a liver protein synthesis inhibitor on plasma SAA levels in a model of accelerated amyloid deposition. Lab Invest 1979; 41: 206-10
13. Hoover KL, Hyde CL, Wenk ML, et al. Ethionine carcinogenesis in CD-1, BALB/c, and C3H mice. Carcinogenesis 1986 Jul; 7 (7): 1143-8
14. Lyon AW, Kisilevsky R. Inhibition of the initiation of hepatic-protein synthesis during ethionine mediated ATP depletion in vivo: modification to ribosomal subunits, evidence of impaired ternary complex formation and a subcellular redistribution of eIF-2-Alpha. Biochim Biophys Acta 1990; 1049: 158-70
15. Araki S, Ikegawa S. Transthyretin and apoA-I amyloidosis. In: Kisilevsky R, Benson MD, Frangione B, et al., editors. Amyloid and amyloidosis 1993. Park Ridge (NJ): The Parthenon Publishing Group, 1994: 422-7
16. Holmgren G, Ericzon BG, Groth CG, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993; 341: 1113-6
17. Kyle RA, Greipp PR, Garton JP, et al. Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine. Am J Med 1985; 79: 708-16
18. Camoriano JK, Greipp PR, Bayer GK, et al. Resolution of acquired factor X deficiency and amyloidosis with melphalan and prednisone therapy. N Engl J Med 1987; 316: 1133-5
19. Gertz MA, Kyle RA. Acute leukemia and cytogenetic abnormalities complicating melphalan treatment of primary systemic amyloidosis. Arch Intern Med 1990; 150: 629-33
20. Merlini G. Treatment of primary amyloidosis. Semin Hematol 1995; 32: 60-79
21. Selkoe DJ. Physiological production of the beta-amyloid protein and the mechanism of alzheimer's disease. Trends Neurosci 1993; 16: 403-9
22. Gandy S, Caporaso G, Buxbaum J, et al. APP processing, Aβ-amyloidogenesis, and the pathogenesis of Alzheimers disease. Neurobiol Aging 1994; 15: 253-6
23. Selkoe DJ. Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. Annu Rev Cell Biol 1994; 10: 373-403
24. Evin G, Beyreuther K, Master CL. Alzheimer's disease amyloid precursor protein (AβPP): proteolytic processing, secretases, and βA4 amyloid production. Amyloid Int J Exp Clin Invest 1994; 1: 263-80
25. Lorenzo A, Yankner BA. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci USA 1994; 91: 12243-7
26. van Broeckhoven CL. Molecular genetics of Alzheimer disease: identification of genes and gene mutations. Eur Neurol 1995; 35: 8-19
27. Jarrett JT, Lansbury PT. Amyloid fibril formation requires a chemically discriminating nucleation event - studies of an amyloidogenic sequence from the bacterial protein OsmB. Biochemistry 1992; 31: 12345-52
28. Come JH, Fraser PE, Lansbury PT. A kinetic model for amyloid formation in the prion diseases - importance of seeding. Proc Natl Acad Sci USA 1993; 90: 5959-63
29. Kelly JW, Lansbury PT. A chemical approach to elucidate the mechanism of transthyretin and β-protein amyloid fibril formation. Amyloid Int J Exp Clin Invest 1994; 1: 186-205
30. Lansbury PT. The molecular mechanism of amyloid formation in Alzheimer's disease. Eur J Med Chem 1995; 30 Suppl.: S621-S63
31. Better OS, Zerner D. Familial Mediterranean fever - diagnosis and treatment. Dtsch Med Wochenschr 1991; 116: 548-52
32. Shohat M, Danon YL, Rotter JI. Familial Mediterranean lever - analysis of inheritance and current linkage data. Am J Med Genet 1992; 44: 183-8
33. Daniels M, Shohat T, Brenner-Ullman A, et al. Familial Mediterranean fever: high gene frequency among the non-Ashkenazic and Ashkenazic Jewish populations in Israel. Am J Med Genet 1995; 55: 311-4
34. Zemer D, Livneh A, Pras M, et al. Familial Mediterranean fever in the colehicine era - the late of one family. Am J Med Genet 1993; 45: 340-4
35. Livneh A, Zemer D, Langevitz P, et al. Colehicine treatment of AA amyloidosis of familial Mediterranean fever: an analysis of factors affecting outcome. Arthritis Rheum 1994; 37: 1804-11
36. Brandwein SR, Sipe JD, Skinner M, et al. Effect of colehicine on experimental amyloidosis in two CBA/J mouse models: chronic inflammatory stimulation and administration of amyloid-enhancing factor during acute inflammation. Lab Invest 1985; 52: 319-25
37. Lyon AW, Narindrasorasak S, Young ID, et al. Co-deposition of basement membrane components during the induction of murine splenic AA amyloid. Lab Invest 1991; 64: 785-90
38. Narindrasorasak S, Altman RA, Gonzalez-DeWhitt P, et al. An interaction between basement membrane and Alzheimer amyloid precursor proteins suggests a role in the pathogenesis of Alzheimer's disease. Lab Invest 1995; 72: 272-82
39. McCubbin WD, Kay CM, Narindrasorasak S, et al. Circular dichroism and fluorescence studies on two murine serum amyloid A proteins. Biochem J 1988; 256: 775-83
40. Fraser PE, Nguyen JT, Chin DT, et al. Effects of sulfate ions on Alzheimer-beta/A4 peptide assemblies - implications for amyloid fibril-proteoglycan interactions. J Neureichem 1992; 59: 1531-40
41. Fraser PE, Kirschner DA, Nguven JT, et al. Binding of sulfated-proleins and alpha-1-antichymotrypsin to Alzheimer Aβ: different actions of amyloid associated proteins. In: Kisilevsky R, Benson MD, Frangione B, et al. editors. Amyloid and amyloidosis 1993. Park Ridge (NJ): The Parthenon Publishing Group, 1994: 341-3
42. De Beer MC, de Beer FC, McCubbin WD, et al. Structural prerequisites for serum amyloid A fibril formation. J Biol Chem 1993; 268: 20606-12
43. Kisilevsky R, Lemieux LJ, Fraser PE, et al. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nature Med 1995; 1: 143-8
44. Burgevin MC, Passat M, Daniel N, et al. Congo Red protects against toxicity of beta-amyloid peptides on rat hippocampal neurones. NeuroReport 1994; 5: 2429-32
45. Pollack SJ, Sadler HJ, Hawtin SR, et al. Sulfated glycosaminoglycans and dyes attenuate the neurotoxic effects of beta-amyloid in rat PC12 cells. Neurosci Lett 1995; 184: 113-6
46. Caughey B, Race RE. Potent inhibition of scrapie-associated PrPaccumulation by Congo Red. J Neurochem 1992; 59: 768-71
47. Caughey B, Brown K, Raymond GJ, et al. Binding of the protease-sensitive form of PrP(prion protein) to sulfated glycosaminoglycan and congo red. J Virol 1994; 68: 2135-41
48. Priola SA, Caughey B. Inhibition of scrapie-associated PrP accumulation - probing the role of glycosuminoglycans in amyloidogenesis. Mol Neurobiol 1994; 8: 113-20
49. Wegelius O. The resolution of amyloid substance. Acta Med Scand 1982; 212: 273-5
50. Tang AL, Davies DR, Wing AJ. Remission of nephrolic syndrome in amyloidosis associated with a hypernephroma. Clin Nephrol 1989; 32: 225-8
51. Perfetti V, Bellolti V, Maggi A, et al. Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman's disease. Am J Hematol 1994; 46: 189-93
52. Ravid M, Shapira J, Lang R, et al. Prolonged dimethylsulphoxide treatment in 13 patients with systemic amyloidosis. Ann Rheum Dis 1982; 41: 587-92
53. Kedar I, Greenwald M, Ravid M. Treatment of experimental murine amyloidosis with dimethyl sulfoxide. Eur J Clin Invest 1977; 7: 149-50
54. van Rijswijk MH, Donker AJM, Ruinen L. Dimethylsulphoxide in amyloidosis. Lancet 1979; i: 207-8
55. Merlini G, Ascari E, Amboldi N, et al. Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci USA 1995; 92: 2959-63
56. Gianni L, Bellotti V, Gianni AM, et al. New drug therapy of amyloidoses: resorption of AL-type deposits with 4′-iodo-4′-deoxydoxorubicin. Blood 1995; 86: 855-61
57. Tennent GA, Lovat LB, Pepys MB. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci USA 1995; 92: 4299-303
58. Gupta-Bansal R, Frederickson RCA, Brunden KR. Proteoglycanmediated inhibition of A beta proteolysis - a potential cause of senile plaque accumulation. J Biol Chem 1995; 270: 18666-71
59. Brandwein SR, Sipe JD, Cohen AS. Combined treatment with terbutaline and aminophylline inhibits experimental amyloid-osis in mice. Arthritis Rheum 1994; 37: 1757-60
60. Lorenzo A, Razzaboni B, Weir GC, et al. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 1994; 368: 756-60
61. Sandler S, Stridsberg M. Chronic exposure of cultured rat pancreatic islets to elevated concentrations of islet amyloid polypeptide (IAPP) causes a decrease in islet DNA content and medium insulin accumulation. Regul Pept 1994; 53: 103-9
62. Westermark P, Johnson KH, O'Brien TD, et al. Islet amyloid polypeptide - a novel controversy in diabetes research. Diabetologia 1992; 35: 297-303
63. Johnson KH, O'Brien TD, Betsholtz C, et al. Islet amyloid polypeptide - mechanisms of amyloidogenesis in the pancreatic islets and potential roles in diabetes mellitus. Lab Invest 1992; 66: 522-35
64. O'Brien TD, Butler PC, Westermark P, et al. Islet amyloid polypeptide - a review of its biology and potential roles in the pathogenesis of diabetes mellitus. Vet Pathol 1993; 30: 317-32
65. Cooper GJS. Areappraisal of current hypotheses concerning the possible roles of amylin in physiology, pathology and therapeutics. Clin Sci 1995; 88: 7-12
66. Goldfarb LG, Brown P. The transmissible spongiform encephalopathies. Ann Rev Med 1995; 46: 57-65
67. Prusiner SB, DeArmond SJ. Prion protein amyloid and neurodegeneration. Amyloid Int J Exp Clin Invest 1995; 2: 39-65
68. Prusiner SB. Biochemistry and genetics of prion proteins. Eur J Med Chem 1995; 30 Suppl.: S11-S50
69. Gal R, Korzets A, Schwartz A, et al. Systemic distribution of beta(2)-microglobulin-derived amyloidosis in patients who undergo long-term hemodialysis - report of seven cases and review of the literature. Arch Pathol Lab Med 1994; 118: 718-21
70. Kisilevsky R. Amyloid and amyloidosis: differences, common themes, and practical considerations. Mod Pathol 1991; 4: 514-8